eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc. (LWAC) is a clinical-stage biopharmaceutical company that reached public markets through a de-SPAC merger with LifeSci Acquisition 2 Corp, a blank-check vehicle sponsored by LifeSci Holdings LLC that completed its initial public offering in 2021. The company is focused on targeted translation regulation as a therapeutic modality in oncology. On June 23, 2023, eFFECTOR filed an 8-K with the Securities and Exchange Commission under accession number 0001193125-23-173792, reflecting its continuing disclosure obligations as a post-combination public company operating in the biopharma sector. Investors and analysts tracking SPAC-originated healthcare issuers can access complete filing histories, sponsor profiles, and deal timelines for LWAC by signing up for full data on SpacDesk.